Fisetin has a small but surprisingly old mood literature. The first dedicated antidepressant study ran in 2011, well before fisetin became known as a senolytic, and it is still the most cited paper in this corner of the research. The findings are real and reasonably consistent. The problem is not that the data are weak, it is that the specific tests used are the ones that have historically been worst at predicting whether something helps actual people.
Key Takeaways
- In two standard mouse despair tests, oral fisetin at 10 and 20 mg/kg reduced immobility time without changing general locomotor activity, meaning the effect was not simply the animals moving more.[1]
- The mechanism traced to monoamines: fisetin raised serotonin and noradrenaline in the frontal cortex and hippocampus, and depleting serotonin beforehand abolished the effect entirely.[1]
- Fisetin inhibited total brain monoamine oxidase activity by 14.7 percent while leaving MAO-B untouched, which is a small effect but a real pharmacological one worth knowing about if you take a serotonergic medication.[1]
- A separate model of inflammation-driven depression found oral fisetin reversed the behavioural changes and lowered IL-1β, IL-6 and TNF-α in the hippocampus and prefrontal cortex.[2]
- For anxiety specifically, the evidence is thinner and stranger: the clearest result is in adult zebrafish, with the effect attributed to 5-HT3 receptor activity.[3]
- No human trial has tested fisetin for depression, anxiety, or any mood outcome. Not one.
The 2012 study that started it
Zhen and colleagues gave mice fisetin by mouth at 10 and 20 mg/kg and ran two behavioural tests: the forced swimming test and the tail suspension test. Both measure how long an animal stays immobile when placed in an inescapable situation, and both are the standard first screen for antidepressant compounds. Fisetin cut immobility time in a dose-dependent way in both tests.[1]
The control they ran matters more than the result. A compound can shorten immobility simply by making an animal jittery and hyperactive, which looks like an antidepressant effect but is not one. The doses that changed immobility did not change locomotor activity, so that explanation is ruled out.
They then went after the mechanism with two manipulations. Pre-treating the mice with p-chlorophenylalanine, which depletes serotonin, completely abolished fisetin’s effect. Direct measurement confirmed that fisetin raised serotonin and noradrenaline in the frontal cortex and hippocampus. That is a monoamine story, and it is the same broad mechanism most conventional antidepressants work through.
The inflammation angle
A 2016 follow-up took a different route. Instead of the plain despair tests, the researchers injected mice with lipopolysaccharide, a bacterial cell wall component that reliably produces both inflammation and depression-like behaviour. Pre-treating with fisetin at 20, 40 and 80 mg/kg by mouth for seven days reversed the behavioural changes and, on measurement, reduced IL-1β, IL-6 and TNF-α in the hippocampus and prefrontal cortex, with the higher dose also suppressing iNOS through NF-κB.[2]
This fits fisetin’s broader profile. Its anti-inflammatory mechanisms are among the better characterised things about it, and the inflammation theory of depression is a legitimate area of research. It also means the mood result may not be a mood-specific effect at all, but a general anti-inflammatory one that happens to show up on a behavioural test.
Anxiety: zebrafish and a docking simulation
The anxiety evidence is much weaker than the depression evidence. The clearest dedicated paper studied fisetin isolated from Bauhinia pentandra in adult zebrafish, reporting anxiolytic behaviour and delayed seizures, with molecular docking suggesting interaction at the 5-HT3A receptor.[3] Zebrafish anxiety models are a legitimate screening tool, but they are a screening tool, several steps further from human relevance than a mouse.
Anxiety-like behaviour has also improved as a secondary finding in mouse studies designed around something else, such as one testing fisetin at 5, 10 and 20 mg/kg against arsenic and fluoride neurotoxicity.[4] That is supportive, but a secondary outcome in a toxicology study is not the same as an anxiety trial.
The problem nobody selling fisetin will mention
The forced swimming test and tail suspension test are famous for a reason that has nothing to do with their accuracy. They are cheap, fast, and almost every compound that eventually failed in human depression trials passed them first. A positive result in these tests tells you a compound is worth investigating. It does not tell you it works.
The second issue is delivery. Two of the more recent mood-adjacent studies did not use plain fisetin at all. They used chitosan nanoparticle formulations, and the epilepsy study was explicit that it was testing subtherapeutic doses of free fisetin against the nanoparticle version precisely because plain fisetin’s solubility and rapid metabolism limit what it can do.[5][6] When researchers reformulate a compound to make it work, that is a statement about the unformulated version. This is the same bioavailability problem that shadows most of the fisetin literature.
The interaction worth taking seriously
Fisetin inhibited brain monoamine oxidase by roughly 15 percent in the 2012 study. That is modest, and it was measured in mice, not people. But if you take an SSRI, SNRI, MAOI, triptan, or any other serotonergic drug, a supplement with measurable MAO activity and a demonstrated ability to raise brain serotonin is not a neutral addition. Nothing in this literature establishes that the combination is dangerous, and nothing in it establishes that it is safe. Talk to whoever prescribes your medication before adding it. Our fisetin drug interactions page covers the wider picture.
What this does and does not support
What the research supports: fisetin has genuine monoaminergic and anti-inflammatory activity in the rodent brain, and that activity produces measurable behavioural changes in standard screening models.
What it does not support: taking fisetin for depression or anxiety. There is no human data, the animal tests used are poor predictors, the doses came from injected or formulated preparations in several cases, and depression is a condition where delaying real treatment carries real cost. If you are considering fisetin for its cognitive or senolytic properties and you also happen to have low mood, this literature is a footnote, not a reason.
References
- The antidepressant-like effect of fisetin involves the serotonergic and noradrenergic system. Behav Brain Res (2012). PMID 22197297
- The effects of fisetin on lipopolysaccharide-induced depressive-like behavior in mice. Metab Brain Dis (2016). PMID 27209403
- Anxiolytic and Anticonvulsant Effects of Fisetin Isolated from Bauhinia pentandra on Adult Zebrafish. Chem Biodivers (2024). PMID 39088251
- Fisetin attenuates arsenic and fluoride subacute co-exposure induced neurotoxicity via regulating TNF-α mediated activation of NLRP3 inflammasome. Neurotoxicology (2023). PMID 37331635
- Fisetin-loaded chitosan nanoparticles ameliorate pilocarpine-induced temporal lobe epilepsy and associated neurobehavioral alterations in mice. Nanomedicine (2024). PMID 38740358
- Nanoformulated fisetin ameliorates Alzheimer’s disease via reducing proinflammatory cytokines and activating the NRF2/HO-1 pathway. Nanomedicine (Lond) (2024). PMID 39552578
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
